Interview: Atox Aims For Reltecimod OK In 2020

 
• By Kevin Grogan

The Israeli biotech is eagerly awaiting Phase III data on its therapy for necrotizing soft tissue infections before the end of 2019.

Timer
Waiting time nearly over for reltecimod data • Source: Shutterstock

More from Anti-infective

More from Therapy Areas